Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
Kymera Therapeutics, Inc.KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical...